⚡🏙️ 混凝土能为城市供电？ 想象一下建筑物、桥梁和道路都能自行发电。 中国东南大学周扬教授领导的研究人员研发出一种水泥-水凝胶复合材料，它就能发电并储存电能。🔋 💡 受植物茎干层状结构的启发，这种材料交替使用水泥层和水凝胶层来增强离子运动。结果如何？它拥有惊人的塞贝克系数 -40.5 mV/K 和 6.6×10⁻² 的 ZT 值——对于如此常见的材料而言，这创下了纪录。 这项创新可以将日常混凝土转化为能源，为自供电建筑和智能基础设施铺平道路。这也是朝着可持续建筑迈出的一大步，在保持城市运转的同时减少排放。 🌍 #智慧城市 #绿色科技 #清洁能源 #建筑未来 #创新 #可持续设计 #混凝土革命 #合成生物测试2025 ⚡🏙️ Concrete That Powers Cities? Imagine buildings, bridges, and roads that generate their own electricity. Researchers at Southeast University, China, led by Professor Zhou Yang, have developed a cement–hydrogel composite that does exactly that — it can produce and store power. 🔋 💡 Inspired by the layered structure of plant stems, the material alternates cement and hydrogel layers to enhance ion movement. The result? A remarkable Seebeck coefficient of −40.5 mV/K and a ZT of 6.6×10⁻² — record performance for such a common material. This innovation could turn everyday concrete into an energy source, paving the way for self-powered buildings and smart infrastructure. It’s also a big step toward sustainable construction, cutting emissions while keeping cities running. 🌍 #SmartCities #GreenTech #CleanEnergy #FutureOfConstruction #Innovation #SustainableDesign #ConcreteRevolution #SynBioBeta2025

More #SynBioBeta2025 research goodness: Take a peek at this poster by Greg Lohman of @NEBiolabs about phage engineering using synthetic mycobacteriophages created with Ansa’s help. linkedin.com/feed/update/urn…

Just wrapped up an amazing time at @SynBioBeta 2025 in #California! Grateful to speak on two very different panels — from anti-aging tech 💊🧬 for astronauts to global leadership in biotech. Inspired by the brilliant minds pushing biology beyond Earth and beyond limits 🚀 #SynBioBeta2025 #SpaceBiology #Aging #Biotech #WomenInSTEM #Innovation

In partnership with Stanford, UNC Chapel Hill, UC Davis, and UC Irvine, this project advances cell-free biocatalysis to enable the commercial production of diverse molecules—fueling the transition to a more sustainable domestic chemicals industry. #SynBioBeta2025 #NSF #Arzeda #AI

🧠 #SynBioBeta2025 에서 논의된 주요 AI 주제들 올해 SynBioBeta는 한 가지를 분명히 보여줬습니다: AI는 지금 우리가 실험으로 검증할 수 있는 범위를 넘어설 만큼의 생물학적 통찰을 생성하고 있다는 것입니다. 제약 요소는 모델의 성능이 아니라, 그 주변의 모든 인프라입니다. 🔬 1. 더 나은 모델이 아니라, 더 나은 데이터가 필요하다. 모두가 차세대 AlphaFold를 만들고 싶어하지만, 실제로 AlphaFold가 기반한 것은 구조화된 고품질의 도메인 특화 데이터, 특히 Negative 데이터(실패 사례 데이터)였습니다. 패널들은 이런 데이터 없이는 기반 모델도 한계에 부딪힐 수밖에 없다고 강조했고, RNA 분야에서 그 문제가 특히 두드러집니다. 🧪 2. 병목은 ‘사고(thinking)’가 아니라 ‘실험(testing)’에 있다. AI는 DBTL(설계-제작-테스트-학습) 사이클의 Design-Build 측면에 수많은 가능성을 쏟아붓고 있습니다. 하지만 Test-Learn 쪽은 액체 처리, 마이크로플루이딕스(microfluidics), 품질관리(QC) 처리량 등의 문제로 현실적인 한계에 부딪히고 있습니다. 여러 세션에서 AI가 수천 개의 설계를 제안해도, 실제로 효율적으로 검증할 수 있는 비율은 극히 적다는 실행 격차 문제가 집중 조명됐습니다. 🏗️ 3. AI는 시스템적 사고가 필요하다 좋은 모델만으로는 충분하지 않습니다. 가치를 실현하려면 **피드백 루프, 자동화, 빠른 반복(iteration)**을 중심으로 기업 전체를 설계해야 합니다. 이번 행사에서 반복적으로 등장한 메시지: 바이오 기업 대부분이 여전히 ‘고정된 파이프라인’ 구조를 유지하고 있다. 이제는 동적인 학습 구조로 전환해야 할 때입니다. 💊 4. 누가 실험을 실행할 것인가? 제약회사의 협업 모델이 변하고 있습니다. Novartis, Terray Therapeutics, Constructive Bio 같은 기업들은 이제 임상 전(preclinical), 혹은 제품 출시 전(pre-product) 단계부터 협업을 모색하고 있습니다. 왜일까요? 나중에 인수하는 것보다 초기에 플랫폼을 함께 설계하는 게 더 저렴하기 때문이고, 제약사의 내부 R&D 사이클보다 스타트업의 반복 속도가 훨씬 빠르기 때문이며, 디자인이 아니라 ‘검증(Validation)’이 실제로 가치를 증명하는 단계이기 때문입니다. ------------------------------------------ 깅코 형님들이(@jrkelly @SynBio1) 매일 하는 얘기 DBTL 중에서 B, T의 중요성이 점점 커지는데, B와 T를 스케일업 하기 위해서는 자동화된 루프가 필요

SynBioBeta2025で当社CEO鈴木が登壇しました！当社のバイオものづくりへの取り組みについて特集いただき、多くの参加者に関心を持っていただけたことを嬉しく思います。これからもバイオエコノミーの実現に向け、事業・技術開発を加速して参ります！

DeSci at #SynBioBeta2025 “Scientists are the most important creators; scientists need to be rock stars.” DeSci commoditizes science, rewards creators, funds fungi & health via crypto 🧬🚀 w/ @NODEfather , @jamessinka , @geoffanders, @Chris_Raggio, @HumerJuliette

The AI and synthetic biology combo at SynBioBeta2025 is a game-changer. Keen to see how it advances materials science!

And that's #SynBioBeta2025 wrapped! Thank you to everyone who made this all happen- to all our sponsors, staff, volunteers and attendees. You are @SynBioBeta. If you missed this years' event, lock in early bird pricing for next year. syntheticbiologysummit.com/g… See you in 2026!

If you missed out on #SynBioBeta2025, get your 2026 tickets now at a super early bird rate. It's been really fun meeting, hanging out and chatting with folks like Jason and Bryan, and I'd love for you to join the fun. syntheticbiologysummit.com/g…

If you missed out on #SynBioBeta2025, get your 2026 tickets now at a super early bird rate. It's been really fun meeting, hanging out and chatting with the pioneers of synbio this year and I'd love for you to join the fun. syntheticbiologysummit.com/g…

The legend @jrkelly at #synbiobeta2025 My @TechBi0 podcast with Jason about AI, Bio and @Ginkgo coming out soon!! #techbio #synbio

If you missed out on #SynBioBeta2025, get your 2026 tickets now at a super early bird rate. It's been really fun meeting, hanging out and chatting with the pioneers of synbio this year and I'd love for you to join the fun. syntheticbiologysummit.com/g…

The main event at #SynBioBeta2025 @bryan_johnson @jrkelly #Longevity #synbio #techbio #dontdie

"RNA remains a black box—especially structurally. While we know around 7,000 protein structures out of 20,000 in humans, we only have 100 RNA structures out of 100,000 possible transcripts. That gap in understanding is exactly why many algorithms struggle to predict RNA shape." @raphaeljlt #SynBioBeta2025

Look forward to speaking at the #SynBioBeta2025 conference in California this week to discuss the potential of our #Anti-Necrotic™ therapeutic to alleviate tissue #degeneration and #aging in space, overcoming the #biological hurdles of long duration #space missions! SynBioBeta

Are you at @SynBioBeta? Today's the final day! Visit IDT booth #401 and other Danaher Corporation operating companies, @moldev at booth #407 and @BCILifeSciences at booth #301. Together, we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology. #synbiobeta2025 #synbiobeta25

Today at 2:30p at #SynBioBeta2025, Complete Genomics' Rob Tarbox joins the breakout session "Deconstructing Cellular Diversity: Single-Cell Sequencing for Drug Discovery and Synthetic Biology" to discuss how single-cell technologies are reshaping precision medicine and synthetic biology. syntheticbiologysummit.com/t…

🧵Glanville also shared that @centivax is exploring broader applications: “We are also looking at a universal immunity for #HIV and #malaria.” #Vaccines #GlobalHealth #SynBioBeta2025 #SynBioBeta @CurlyJungleJake

“We are 9 months away from a clinical trial of a universal #influenza #vaccine,” said Jacob Glanville of @centivax at #SynBioBeta2025. A big moment in the making—shared on stage with Amanda Cashin (Prisma) and @DeanKamen (ARMI). #SynBioBeta #Vaccines #Biotech @CurlyJungleJake